Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia
- PMID: 35131036
- DOI: 10.1016/S2213-8587(22)00038-9
Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia
Conflict of interest statement
TM-MT was supported by research funding from the UK National Institute for Health Research (NIHR), NIHR Imperial Biomedical Research Centre, JP Moulton Charitable Foundation, and Leadiant Pharmaceuticals; and is a consultant for and shareholder in Zihipp, a company that develops gut hormone analogues of GLP-1, oxyntomodulin, glucose-dependent insulinotropic peptide, and peptide YY for obesity and diabetes. BK declares no competing interests.
Comment on
-
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206. doi: 10.1016/S2213-8587(22)00008-0. Epub 2022 Feb 4. Lancet Diabetes Endocrinol. 2022. PMID: 35131037 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
